Press Room

BOS cmc 2017 (Bio2Business)

Start
Tuesday, June 27, 2017 - 08:00
End
Wednesday, June 28, 2017 - 16:00
Location: Basel, Switzerland
Spray Drying Development by Design | Hovione

Hovione will be attending BOS cmc 2017 in Basel, Switzerland. In addition, on day 2 Marco Gil Senior Director Commercial Services) will be a speaker.

HOVIONE PRESENTATION

Title: Development by Design

Date: Wednesday, 28th June 2017

Time: 10.45h

Marco Gil picture Hovione Senior VP Sales and Marketing

Marco Gil

Co-CEO, Senior VP - Sales & Marketing

Dr. Marco Gil has over 20 years of experience in the pharmaceutical CDMO industry. Since joining Hovione in 2007, he has held several senior management positions, including Director of R&D Process Chemistry and Site General Manager of Hovione’s New Jersey facility in the United States, where he led operations and strategic growth initiatives in one of the company’s key markets. Between 2017 and 2022, Dr. Marco Gil held leadership roles in Sales and Business Development, contributing to the expansion of Hovione’s integrated offering and global customer partnerships.

Since May 2022, he has served as Senior Vice-President of Sales & Marketing, leading Hovione’s global commercial strategy and market positioning, combining deep scientific expertise with extensive operational and business knowledge in the CDMO sector.

Dr. Marco Gil holds a degree in Chemical Engineering and a Ph.D. in Chemistry from the Technical University of Lisbon.

 

 

 

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Paul Dunne will be pleased to meet you.

paul-dunne-photo

Paul Dunne

Business Development Manager

You might be also interested in

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026